A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].

Inherited and somatic mutations in the adenomatous polyposis coli occur in most colon cancers, leading to activation of beta-catenin-responsive genes. To identify small molecule antagonists of this pathway, we challenged transformed colorectal cells with a secondary structure-templated chemical library, looking for compounds that inhibit a beta-catenin-responsive reporter. We identified ICG-001, a small molecule that down-regulates beta-catenin/T cell factor signaling by specifically binding to cyclic AMP response element-binding protein. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells, and is efficacious in the Min mouse and nude mouse xenograft models of colon cancer.

[1]  Michael J. Eck,et al.  Structure of a human Tcf4–β-catenin complex , 2001, Nature Structural Biology.

[2]  T. Waldman,et al.  Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. , 2002, Molecular cancer therapeutics.

[3]  William I. Weis,et al.  The Structure of the β-Catenin/E-Cadherin Complex and the Molecular Basis of Diverse Ligand Recognition by β-Catenin , 2001, Cell.

[4]  D. Livingston,et al.  Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.

[5]  Randall T. Moon,et al.  The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. , 2000, The Journal of cell biology.

[6]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[7]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[8]  S. Minucci,et al.  Retinoid receptors in health and disease: co-regulators and the chromatin connection. , 1999, Seminars in cell & developmental biology.

[9]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[10]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[11]  C. Hui,et al.  Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis. , 1999, The International journal of developmental biology.

[12]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[13]  D. M. Ferkey,et al.  Tcf4 can specifically recognize β-catenin using alternative conformations , 2001, Nature Structural Biology.

[14]  B. Gumbiner,et al.  Adhesion signaling: How β-catenin interacts with its partners , 2001, Current Biology.

[15]  H. Clevers,et al.  Survivin and molecular pathogenesis of colorectal cancer , 2003, The Lancet.

[16]  K. Tanaka,et al.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  F. Pierre,et al.  Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  Hans C Clevers,et al.  Molecular causes of colon cancer , 2002, European journal of clinical investigation.

[19]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[20]  Kris Vleminckx,et al.  The p300/CBP acetyltransferases function as transcriptional coactivators of β‐catenin in vertebrates , 2000, The EMBO journal.

[21]  W. Bodmer,et al.  Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. , 2002, British medical bulletin.

[22]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[23]  R. Nusse,et al.  Mechanisms of Wnt signaling in development. , 1998, Annual review of cell and developmental biology.

[24]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[25]  Lin Li,et al.  Chromatin immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. , 2003, Methods.

[26]  J. Urban,et al.  Highly efficient and versatile synthesis of libraries of constrained β-strand mimetics , 1998 .

[27]  T. A. Graham,et al.  Crystal Structure of a β-Catenin/Tcf Complex , 2000, Cell.

[28]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[29]  J. Behrens,et al.  Control of β‐Catenin Signaling in Tumor Development , 2000 .

[30]  N. Perrimon,et al.  The Promise and Perils of Wnt Signaling Through β-Catenin , 2002, Science.

[31]  Jonas Wittwer,et al.  Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5 , 2003, The EMBO journal.

[32]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[33]  R. Fine,et al.  A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. , 2002, Biochemical pharmacology.

[34]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[35]  D. Livingston,et al.  p300 Interacts with the Nuclear Proto-Oncoprotein SYT as Part of the Active Control of Cell Adhesion , 2000, Cell.

[36]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[37]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[39]  H. Brantjes,et al.  TCF: Lady Justice Casting the Final Verdict on the Outcome of Wnt Signalling , 2002, Biological chemistry.